• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

儿童和青少年初发局限性滑膜肉瘤复发后的挽救率和预后因素。

Salvage rates and prognostic factors after relapse in children and adolescents with initially localised synovial sarcoma.

机构信息

Pediatric Oncology Unit, Fondazione IRCCS Istituto Nazionale Tumori, Via G. Venezian, Milan, Italy.

出版信息

Eur J Cancer. 2012 Dec;48(18):3448-55. doi: 10.1016/j.ejca.2012.06.017. Epub 2012 Jul 24.

DOI:10.1016/j.ejca.2012.06.017
PMID:22835783
Abstract

BACKGROUND

Previous studies have reported a poor outcome for synovial sarcoma patients whose tumours relapse.

METHODS

This study analysed 44 relapsing cases in a series of 118 consecutive patients <21 yr of age with non-metastatic synovial sarcoma prospectively enrolled in Italian paediatric protocols between 1979 and 2006. In an effort to identify a possible risk-adapted stratification enabling a better planning of second-line treatment, the relapsing patients' outcome was analysed vis-à-vis their clinical picture at onset, first-line treatments, clinical findings at the time of first relapse and second-line treatment modalities.

RESULTS

The first event was a local recurrence in only 15 cases, and metastatic in 29 (associated with local relapse too in 7 cases). The time to relapse ranged from 4 to 108 months (median 20 months). Overall survival was 29.7% and 21.0% five and ten years after relapsing, respectively. The variables influencing survival were the timing and type of relapse (combined) and the chances of a secondary remission, which correlated strongly with the feasibility of complete surgery.

CONCLUSIONS

Our study confirmed a largely unsatisfactory prognosis after recurrences in children and adolescents with synovial sarcoma: the chances of survival can be estimated on the basis of several variables for the purposes of planning risk-adapted salvage protocols. An aggressive surgical approach should be recommended. New effective systemic agents are warranted, and experimental therapies can be offered to patients with little chance of salvage.

摘要

背景

先前的研究报告显示,滑膜肉瘤患者肿瘤复发的预后较差。

方法

本研究分析了 1979 年至 2006 年期间,意大利儿科方案前瞻性纳入的 118 例连续非转移性滑膜肉瘤患者中,44 例复发患者的病例。为了确定一种可能的风险分层,以便更好地规划二线治疗,分析了复发患者的临床特征、一线治疗、首次复发时的临床发现和二线治疗方式。

结果

首次事件仅为局部复发 15 例,远处转移 29 例(其中 7 例合并局部复发)。复发时间为 4 至 108 个月(中位数为 20 个月)。复发后 5 年和 10 年的总生存率分别为 29.7%和 21.0%。影响生存的变量是复发的时间和类型(联合)以及继发性缓解的机会,这与完全手术的可行性密切相关。

结论

我们的研究证实了儿童和青少年滑膜肉瘤复发后的预后仍然很差:根据几个变量可以估计生存的机会,以便为制定风险适应的挽救方案提供参考。应推荐积极的手术方法。需要新的有效的系统治疗药物,并且可以为挽救机会较小的患者提供实验性治疗。

相似文献

1
Salvage rates and prognostic factors after relapse in children and adolescents with initially localised synovial sarcoma.儿童和青少年初发局限性滑膜肉瘤复发后的挽救率和预后因素。
Eur J Cancer. 2012 Dec;48(18):3448-55. doi: 10.1016/j.ejca.2012.06.017. Epub 2012 Jul 24.
2
Treatment outcome in children and adolescents with relapsed Hodgkin lymphoma--results of the UK HD3 relapse treatment strategy.儿童和青少年复发性霍奇金淋巴瘤的治疗结果——英国 HD3 复发治疗策略的结果。
Br J Haematol. 2014 May;165(4):534-44. doi: 10.1111/bjh.12768. Epub 2014 Feb 7.
3
Treatment at relapse for synovial sarcoma of children and adolescents: A multi-institutional European retrospective analysis.儿童和青少年滑膜肉瘤复发后的治疗:多机构欧洲回顾性分析。
Pediatr Blood Cancer. 2024 Jul;71(7):e31038. doi: 10.1002/pbc.31038. Epub 2024 Apr 28.
4
Paediatric non-rhabdomyosarcoma soft tissue sarcomas: the prospective NRSTS 2005 study by the European Pediatric Soft Tissue Sarcoma Study Group (EpSSG).儿科非横纹肌肉瘤软组织肉瘤:欧洲儿科软组织肉瘤研究组(EpSSG)的前瞻性 NRSTS 2005 研究。
Lancet Child Adolesc Health. 2021 Aug;5(8):546-558. doi: 10.1016/S2352-4642(21)00159-0. Epub 2021 Jun 30.
5
Synovial sarcoma relapses in children and adolescents: prognostic factors, treatment, and outcome.滑膜肉瘤患儿和青少年的复发:预后因素、治疗和结局。
Pediatr Blood Cancer. 2014 Aug;61(8):1387-93. doi: 10.1002/pbc.25001. Epub 2014 Mar 24.
6
Adjuvant chemotherapy decreases and postpones distant metastasis in extremity stage IIB/III synovial sarcoma patients.辅助化疗可降低和延迟肢体 IIB/III 期滑膜肉瘤患者的远处转移。
J Surg Oncol. 2012 Aug 1;106(2):162-8. doi: 10.1002/jso.23061. Epub 2012 Feb 1.
7
Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.复发侵袭性淋巴瘤的治疗:含与不含高剂量治疗及干细胞救援的方案
Cancer Chemother Pharmacol. 2002 May;49 Suppl 1:S13-20. doi: 10.1007/s00280-002-0447-1. Epub 2002 Apr 12.
8
[Therapeutic options for synovial sarcoma].[滑膜肉瘤的治疗选择]
Orv Hetil. 2015 May 31;156(22):875-80. doi: 10.1556/650.2015.30166.
9
Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial.基于组织学分型的新辅助化疗对比标准化疗用于高危软组织肉瘤患者(ISG-STS 1001):一项国际、开放标签、随机、对照、III 期、多中心试验
Lancet Oncol. 2017 Jun;18(6):812-822. doi: 10.1016/S1470-2045(17)30334-0. Epub 2017 May 9.
10
Regional deep hyperthermia for salvage treatment of children and adolescents with refractory or recurrent non-testicular malignant germ-cell tumours: an open-label, non-randomised, single-institution, phase 2 study.局部深部高热治疗儿童和青少年难治性或复发性非睾丸生殖细胞肿瘤的挽救治疗:一项开放标签、非随机、单中心、2 期研究。
Lancet Oncol. 2013 Aug;14(9):843-52. doi: 10.1016/S1470-2045(13)70271-7. Epub 2013 Jul 1.

引用本文的文献

1
Treatment at Relapse for Synovial Sarcoma of Children, Adolescents and Young Adults: From the State of Art to Future Clinical Perspectives.儿童、青少年和青年滑膜肉瘤复发时的治疗:从现状到未来临床展望
Cancer Manag Res. 2023 Oct 27;15:1183-1196. doi: 10.2147/CMAR.S404371. eCollection 2023.
2
Intrathoracic synovial sarcoma with BRAF V600E mutation.胸腔内滑膜肉瘤伴 BRAF V600E 突变。
Oncotarget. 2023 Jul 7;14:703-708. doi: 10.18632/oncotarget.28475.
3
Haploidentical hematopoietic stem cell transplantation as individual treatment option in pediatric patients with very high-risk sarcomas.
单倍体相合造血干细胞移植作为高危小儿肉瘤患者的个体化治疗选择
Front Oncol. 2023 Feb 21;13:1064190. doi: 10.3389/fonc.2023.1064190. eCollection 2023.
4
Pediatric Non-Rhabdomyosarcoma Soft Tissue Sarcomas: Standard of Care and Treatment Recommendations from the European Paediatric Soft Tissue Sarcoma Study Group (EpSSG).儿童非横纹肌肉瘤软组织肉瘤:欧洲儿科软组织肉瘤研究组(EpSSG)的治疗标准与建议
Cancer Manag Res. 2022 Sep 23;14:2885-2902. doi: 10.2147/CMAR.S368381. eCollection 2022.
5
Patterns of care and outcomes of 417 patients with METAstatic SYNovial sarcoma (METASYN): real-life data from the French Sarcoma Group (FSG).417 例转移性滑膜肉瘤(METASYN)患者的治疗模式和结局:来自法国肉瘤研究组(FSG)的真实数据。
ESMO Open. 2022 Apr;7(2):100402. doi: 10.1016/j.esmoop.2022.100402. Epub 2022 Feb 21.
6
CDK9 as a Valuable Target in Cancer: From Natural Compounds Inhibitors to Current Treatment in Pediatric Soft Tissue Sarcomas.CDK9作为癌症的一个重要靶点:从天然化合物抑制剂到小儿软组织肉瘤的当前治疗方法
Front Pharmacol. 2020 Aug 13;11:1230. doi: 10.3389/fphar.2020.01230. eCollection 2020.
7
Primary Synovial Sarcoma Presenting as a Huge Mass: A Report of a Rare Case and Review of Literature.以巨大肿块形式出现的原发性滑膜肉瘤:1例罕见病例报告及文献复习
Arch Bone Jt Surg. 2020 May;8(3):454-456. doi: 10.22038/ABJS.2019.14130.
8
Primary advanced pulmonary synovial sarcoma treated with a multidisciplinary approach.采用多学科方法治疗的原发性晚期肺滑膜肉瘤。
Int Cancer Conf J. 2020 Feb 14;9(2):72-76. doi: 10.1007/s13691-020-00399-2. eCollection 2020 Apr.
9
Surgical management and outcome of synovial sarcoma in the spine.脊柱滑膜肉瘤的外科治疗和预后。
World J Surg Oncol. 2018 Aug 27;16(1):175. doi: 10.1186/s12957-018-1471-x.
10
Imaging features of primary and metastatic extremity synovial sarcoma: a single institute experience of 78 patients.原发性和转移性肢体滑膜肉瘤的影像学特征:一家机构78例患者的经验
Br J Radiol. 2015 Feb;88(1046):20140608. doi: 10.1259/bjr.20140608. Epub 2014 Nov 28.